Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop.

Huse JT, Wallace M, Aldape KD, Berger MS, Bettegowda C, Brat DJ, Cahill DP, Cloughesy T, Haas-Kogan DA, Marra M, Miller CR, Nelson SJ, Salama SR, Soffietti R, Wen PY, Yip S, Yen K, Costello JF, Chang S.

Neuro Oncol. 2014 Jan;16(2):173-8. doi: 10.1093/neuonc/not229. Epub 2013 Dec 4. Review.

2.

The role of chemotherapy in the treatment of low-grade glioma. A review of the literature.

Neyns B, Sadones J, Chaskis C, De Ridder M, Keyaerts M, Veld PI, Michotte A.

Acta Neurol Belg. 2005 Sep;105(3):137-43. Review.

PMID:
16255151
3.

Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux.

Lin F, de Gooijer MC, Hanekamp D, Brandsma D, Beijnen JH, van Tellingen O.

CNS Oncol. 2013 May;2(3):271-88. doi: 10.2217/cns.13.15. Review.

PMID:
25054467
4.

Targeted therapy in pediatric low-grade glioma.

Kilday JP, Bartels UK, Bouffet E.

Curr Neurol Neurosci Rep. 2014 Apr;14(4):441. doi: 10.1007/s11910-014-0441-0. Review.

PMID:
24604059
5.

Updates from the 2013 Society for Neuro-Oncology annual and World Federation for Neuro-Oncology quadrennial meeting.

Lukas RV, Amidei C.

Tumori. 2014 May-Jun;100(3):358-62. doi: 10.1700/1578.17228. Review.

PMID:
25076251
6.

Role of tyrosine kinase inhibitors in the management of high-grade gliomas.

Ahluwalia MS, Patel M, Peereboom DM.

Expert Rev Anticancer Ther. 2011 Nov;11(11):1739-48. doi: 10.1586/era.11.166. Review.

PMID:
22050023
7.

Pediatric low-grade gliomas: how modern biology reshapes the clinical field.

Bergthold G, Bandopadhayay P, Bi WL, Ramkissoon L, Stiles C, Segal RA, Beroukhim R, Ligon KL, Grill J, Kieran MW.

Biochim Biophys Acta. 2014 Apr;1845(2):294-307. doi: 10.1016/j.bbcan.2014.02.004. Epub 2014 Feb 28. Review.

8.

Somatic intronic microsatellite loci differentiate glioblastoma from lower-grade gliomas.

Karunasena E, McIver LJ, Rood BR, Wu X, Zhu H, Bavarva JH, Garner HR.

Oncotarget. 2014 Aug 15;5(15):6003-14.

9.

Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.

van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, Armstrong T, Choucair A, Waldman AD, Gorlia T, Chamberlain M, Baumert BG, Vogelbaum MA, Macdonald DR, Reardon DA, Wen PY, Chang SM, Jacobs AH.

Lancet Oncol. 2011 Jun;12(6):583-93. doi: 10.1016/S1470-2045(11)70057-2. Epub 2011 Apr 5. Review.

PMID:
21474379
10.

Glioma-associated stem cells: a novel class of tumor-supporting cells able to predict prognosis of human low-grade gliomas.

Bourkoula E, Mangoni D, Ius T, Pucer A, Isola M, Musiello D, Marzinotto S, Toffoletto B, Sorrentino M, Palma A, Caponnetto F, Gregoraci G, Vindigni M, Pizzolitto S, Falconieri G, De Maglio G, Pecile V, Ruaro ME, Gri G, Parisse P, Casalis L, Scoles G, Skrap M, Beltrami CA, Beltrami AP, Cesselli D.

Stem Cells. 2014 May;32(5):1239-53. doi: 10.1002/stem.1605.

11.

Tailoring chemotherapy for low-grade gliomas.

Galanis E.

Oncology (Williston Park). 2014 Dec;28(12):1052, 1071. No abstract available.

12.

Improving outcomes for neurofibromatosis 1-associated brain tumors.

Brossier NM, Gutmann DH.

Expert Rev Anticancer Ther. 2015 Apr;15(4):415-23. doi: 10.1586/14737140.2015.1009043. Epub 2015 Feb 5. Review.

PMID:
25652347
13.

Current and future directions for Phase II trials in high-grade glioma.

Alexander BM, Lee EQ, Reardon DA, Wen PY.

Expert Rev Neurother. 2013 Apr;13(4):369-87. doi: 10.1586/ern.12.158. Review.

PMID:
23545053
14.

Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.

Laffaire J, Everhard S, Idbaih A, Crinière E, Marie Y, de Reyniès A, Schiappa R, Mokhtari K, Hoang-Xuan K, Sanson M, Delattre JY, Thillet J, Ducray F.

Neuro Oncol. 2011 Jan;13(1):84-98. doi: 10.1093/neuonc/noq110. Epub 2010 Oct 5.

15.

IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.

Gorovets D, Kannan K, Shen R, Kastenhuber ER, Islamdoust N, Campos C, Pentsova E, Heguy A, Jhanwar SC, Mellinghoff IK, Chan TA, Huse JT.

Clin Cancer Res. 2012 May 1;18(9):2490-501. doi: 10.1158/1078-0432.CCR-11-2977. Epub 2012 Mar 13.

16.

Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.

Taylor JW, Chi AS, Cahill DP.

Oncology (Williston Park). 2013 Jun;27(6):504-14. Review.

17.

Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system.

Figarella-Branger D, Bouvier C, de Paula AM, Mokhtari K, Colin C, Loundou A, Chinot O, Metellus P.

J Neurooncol. 2012 Nov;110(2):205-13. doi: 10.1007/s11060-012-0953-x. Epub 2012 Aug 14.

PMID:
22890969
18.

Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.

Hargrave D.

Br J Neurosurg. 2009 Aug;23(4):351-63. doi: 10.1080/02688690903158809. Review.

PMID:
19637006
19.

Pediatric high-grade glioma: molecular genetic clues for innovative therapeutic approaches.

Rood BR, MacDonald TJ.

J Neurooncol. 2005 Dec;75(3):267-72. Review.

PMID:
16195804
20.

Chemotherapy for low-grade gliomas.

Reddy AT, Packer RJ.

Childs Nerv Syst. 1999 Oct;15(10):506-13. Review.

PMID:
10550582
Items per page

Supplemental Content

Write to the Help Desk